Canada markets close in 2 hours 39 minutes

BetterLife Pharma Inc. (BETR.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.12000.0000 (0.00%)
As of 03:59PM EDT. Market open.
Full screen
Previous Close0.1200
Open0.0000
Bid0.1250 x N/A
Ask0.1450 x N/A
Day's Range0.1200 - 0.1200
52 Week Range0.0500 - 0.1950
Volume0
Avg. Volume79,097
Market Cap15.536M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateSept 25, 2024 - Sept 30, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BetterLife Announces Fully Subscribed Private Placement Financing

    VANCOUVER, British Columbia, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, announces that it intends to complete a fully subscribed non-brokered private placement offering (the “Private Placement”) of $1,100,000. The Private Placement will comprise of units issued at a pri

  • GlobeNewswire

    BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent

    VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of 2-bromo-LSD (BETR-001), a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), today announced the publication of its patent entitled “Methods of treating mental or mood disorders using 2-bromo-LSD” (Publication No. US-2024-0058326-A1) by the United States Patent and

  • GlobeNewswire

    Amendment of Disclosures in Past Management Information Circulars

    VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to